Click to Share
 
 
  1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution
Filter News
Show All Results
News By Country
News By Tag
Vaccine Remove
Related Tags


September 2014
Th We Tu Mo Su Sa Fr
18 17 16 15 14 13 12

vaccine Press Releases

  + XML/RSS  



By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Develop in house Sales-Force for Blockbuster REMUNE HIV/AIDS Vaccine Commercialization

By SMi Group
Cancer Vaccines 2014; Quantify Strategies to Enhance Cancer Vaccine Research and Development, 15th - 16 September, London UK

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Seek FDA Approval for Expanded Use of Blockbuster HIV/AIDS Vaccine REMUNE for HIV/AIDS Monotherapy as it produces huge green shoots of CD8+ T cells Killer White Blood Cells

By Strategic Book Publishing and Rights Co, LLC
Strategic Book Publishing & Rights Agency is pleased to announce the release of its newest title, The Divergence Conspiracy, by author Keith Bottin.

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Announces NeuroVax Granted Fast Track FDA Designation for SPMS

By Immune Response BioPharma Inc.
Immune Response BioPharma, Inc. Announces its Flagship HIV/AIDS Vaccine REMUNE Granted Orphan Designation for Pediatric HIV/AIDS Therapeutic Vaccination by the FDA.

By Immune Response BioPharma
Immune Response BioPharma Sets U.S. REMUNE Pricing Range $75-250 Per Dose with a Target of $100 or Less, Goal of $50 per dose, Once Commercial Manufacturing & Stockpiling is Secured on a Large Scale or a New Manufacturing Plant is Built.

By Immune Response BioPharma
Immune Response BioPharma, Inc., Announces its Plans to Develop Annual Preventative HIV/AIDS Vaccine RemuneVax IR-2020 Based on Current Mutated HIV Strain for Preventative Use.

By SMi Group
Development, manufacture and regulation of pre-filled syringes and injector devices: presentations from Merck, Pfizer, Roche, Medimmune and others

By Kansas City Star Books
Kansas Journalist Andy Marso Chronicles Long Road Back to Health in New Book "Worth the Pain: How Meningitis Nearly Killed Me--Then Changed My Life for the Better"

By SMI Group
SMi's announce record breaking attendance at Cancer Vaccines 2013 which returns in 2 weeks.

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. IR103 Phase II Study Results CTN 203 or IR103-111 REMUNEX Provides Maximum Effect in Patients Treated with REMUNE + Amplivax HIV/AIDS Vaccine.

By SMi Group
Vivavacs SAS to Present at 2013 Cancer Vaccines Summit, London

By The Arizona Partnership for Immunization
The Arizona Partnership for Immunization (TAPI) honored 61 individuals, organizations, and initiatives during the 17th Annual Arizona Big Shots awards dinner held on April 17, 2013 at the Phoenix Country Club. Over 325 people attended the event.

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Seek Emergency Approval of REMUNE in Thailand & Begin Stockpiling HIV/AIDS Vaccine

By Travel Safe Clinic
Biological E, one of the leading Indian vaccine manufacturers, has launched a safe and effective vaccine against Japanese Encephalitis, a deadly infectious disease and the leading cause of Acute Encephalitis.

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Announces New ZORCELL Psoriasis Vaccine Phase IIb Study Safety & Efficacy 350 Patients ZORCELL + Methotrexate 6 Months Study.

By IMARC Group
The strong growth of the global biologicals market is expected to create a huge demand for efficient cold chain logistic services.

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Develop Zorcell Psoriasis Vaccine the First Vaccine for Psoriasis & Reviews Phase II Results

By IMARC Group
A new report from IMARC Group expects the market for cold chain logistic services to grow at a CAGR of 8% during 2011-2017.

All Press Releases

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Develop in house Sales-Force for Blockbuster REMUNE HIV/AIDS Vaccine Commercialization

By SMi Group
Cancer Vaccines 2014; Quantify Strategies to Enhance Cancer Vaccine Research and Development, 15th - 16 September, London UK

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Seek FDA Approval for Expanded Use of Blockbuster HIV/AIDS Vaccine REMUNE for HIV/AIDS Monotherapy as it produces huge green shoots of CD8+ T cells Killer White Blood Cells

By Strategic Book Publishing and Rights Co, LLC
Strategic Book Publishing & Rights Agency is pleased to announce the release of its newest title, The Divergence Conspiracy, by author Keith Bottin.

By Hemispherx Biopharma
Non-Human Primate Animal Testing Planned as This Deadly New Virus Now Reaches The United States and Southeast Asia, and Disease Incidence Accelerates

By Gold Law Firm LLC
National Law Firm Settles Flu Vaccine Injury Petition under the National Vaccine Injury Compensation Program. Many are not aware of Compensation Program and the short, strict deadlines that must be met in order to qualify.

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Announces NeuroVax Granted Fast Track FDA Designation for SPMS

By Immune Response BioPharma Inc.
Immune Response BioPharma, Inc. Announces its Flagship HIV/AIDS Vaccine REMUNE Granted Orphan Designation for Pediatric HIV/AIDS Therapeutic Vaccination by the FDA.

By Immune Response BioPharma
Immune Response BioPharma Sets U.S. REMUNE Pricing Range $75-250 Per Dose with a Target of $100 or Less, Goal of $50 per dose, Once Commercial Manufacturing & Stockpiling is Secured on a Large Scale or a New Manufacturing Plant is Built.

By Immune Response BioPharma
Immune Response BioPharma, Inc., Announces its Plans to Develop Annual Preventative HIV/AIDS Vaccine RemuneVax IR-2020 Based on Current Mutated HIV Strain for Preventative Use.

By PRN.FM
Bill Gates and the University of Pittsburgh data mining project to convince legislators to make the vaccination of all Americans mandatory.

By SMi Group
Development, manufacture and regulation of pre-filled syringes and injector devices: presentations from Merck, Pfizer, Roche, Medimmune and others

By American Academy of Neurology
A vaccine used to prevent tuberculosis in other parts of the world may help prevent multiple sclerosis (MS) in people who show the beginning signs of the disease, according to a new study published in the December 4, 2013, online issue of Neurology®,...

By Kansas City Star Books
Kansas Journalist Andy Marso Chronicles Long Road Back to Health in New Book "Worth the Pain: How Meningitis Nearly Killed Me--Then Changed My Life for the Better"

By PRN.fm
Gary Null & Richard Gale Progressive Radio Network, November 15, 2013

By visiongain
A new report by visiongain predicts that the world market for vaccines will reach $48bn in 2015. From this market, vaccine contract manufacturing will reach $0.62bn in 2015.

By Organization of Teratology Information Specialists
Tdap Vaccine During Pregnancy Provides Some Protection To Newborns

By SMI Group
SMi's announce record breaking attendance at Cancer Vaccines 2013 which returns in 2 weeks.

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Seek Fast Track & Orphan Designation of NeuroVax for SPMS to Expand Novel use of MS Vaccine Treatment

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc., has notified the MCC of South Africa that IRBP will Seek Emergency Approval of REMUNE in S.A. as well begin stockpiling & manufacturing the HIV/AIDS vaccine once we have secured a corporate partner in the region.

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. IR103 Phase II Study Results CTN 203 or IR103-111 REMUNEX Provides Maximum Effect in Patients Treated with REMUNE + Amplivax HIV/AIDS Vaccine.

By SMi Group
Vivavacs SAS to Present at 2013 Cancer Vaccines Summit, London

By Fast Market Research, Inc.
Pharmaceutical giants GlaxoSmithKline (GSK) and Merck are fighting it out in the vaccination market, as countries pick sides in their cervical cancer vaccination programs, states a new report by research and consulting firm GBI Research.

By The Arizona Partnership for Immunization
The Arizona Partnership for Immunization (TAPI) honored 61 individuals, organizations, and initiatives during the 17th Annual Arizona Big Shots awards dinner held on April 17, 2013 at the Phoenix Country Club. Over 325 people attended the event.

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Seek Emergency Approval of REMUNE in Thailand & Begin Stockpiling HIV/AIDS Vaccine

By NJ Aid for Animals
NJ Aid for Animals’ Delivers Lifesaving Vaccines for Camden Animals and Introduces “Lost No More” at its Spring...

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Seek Orphan Designation of NeuroVax for Pediatric Multiple Sclerosis to Expand Use of Novel Vaccine Treatment. Immune Response BioPharma, Inc.

By RF Media
As part of the United Nations Foundation Shot@Life campaign, Lee Reyes-Fournier added her support to nearly 100 doctors, advocates and bloggers committed to seeing that every child in the world has a chance at life by receiving their vaccinations.

By Travel Safe Clinic
Biological E, one of the leading Indian vaccine manufacturers, has launched a safe and effective vaccine against Japanese Encephalitis, a deadly infectious disease and the leading cause of Acute Encephalitis.

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Announces New ZORCELL Psoriasis Vaccine Phase IIb Study Safety & Efficacy 350 Patients ZORCELL + Methotrexate 6 Months Study.

By IMARC Group
The share of temperature sensitive healthcare products in the global healthcare market is expected to reach 23% by 2017.

By IMARC Group
The strong growth of the global biologicals market is expected to create a huge demand for efficient cold chain logistic services.

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Develop Zorcell Psoriasis Vaccine the First Vaccine for Psoriasis & Reviews Phase II Results

By IMARC Group
A new report from IMARC Group expects the market for cold chain logistic services to grow at a CAGR of 8% during 2011-2017.

By Organization of Teratology Information Specialists
UNT Experts Available For Questions Regarding The Risk Of Meningitis Vaccine During Pregnancy

By Fast Market Research, Inc.
New Pharmaceuticals research report from Datamonitor is now available from Fast Market Research

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Review of Blockbuster RA Vaccine RAVAX Phase 2B 340 Patient Study Results Demonstrated a 50% Improvement in Patients Vaccinated with RAVAX.

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Provides Blockbuster RAVAX Phase III Study in RA Update With Inadequate Response to Humira or Enbrel now Available at www.immuneresponse.net

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Announces Formulation Changes to Blockbuster RA Drug RAVAX Adds 4th Peptide for Potent RA Vaccine

By TravelSafe Clinic, Charak Clinics
Delhi, National Capital Region, is now served by its first Travel Health Clinic registered with the International Society for Travel Medicine (ISTM). TravelSafe Clinic, is founded by Dr Gaurav Gupta, who is the foremost Travel Health Doctor in India.

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Posts 1st Half 2012 Results Highlights include IRBP Granted U.S. Patent 8,053,197 for Auto-Immune Diseases & Plans for a Phase 2B NeuroVax Study and a Phase 3 RAVAX Study for RA.

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. On the Move Plans Listing on German Exchanges to Fund Blockbuster MS Drug NeuroVax & Pipeline

By Bharatbook
Bharatbook.com introduces a report " 2012 Deep Research Report on China Influenza Vaccine Industry " the report also introduced 8Million Pieces/year Influenza Vaccine project Feasibility analysis.

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Terminates Blockbuster MS Drug NeuroVax Partnership Discusions With GSK

By enRight PR
“Vaccines play a crucial role in the eradication of diseases that affect millions of lives worldwide. The GCE Grant will help us accelerate the pace of research programs .” Dr. Krishna Ella, Co-Founder of Ella Foundation said.

By Cambridge Healthtech Institute
A Two Day Event Focusing on the Challenges with Vaccine Delivery Systems

By Cambridge Healthtech Institute
A Two Day Event Focusing on the Challenges in Vaccine Development

By Bio-IT World
Conference Short Course on Knowledge-Based Systems in Bioinformatics

By Cambridge Healthtech Institute
Hear Strategies and Technologies to Advance Vaccine Development

By Fast Market Research, Inc.
Europe to Strengthen Its Position as the Single Largest Market for Animal Vaccines Due To Highly Organized Livestock Farms



Page:

Page updated every 10 minutes


  1. SiteMap
  2. Contact PRLog
  3. Privacy Policy
  4. Terms of Service
  5. Copyright Notice
  6. About
  7. Advertise
Like PRLog?
9K2K1K
Click to Share